MK-801 interaction with the 5-HT transporter: A real-time study in brain slices using fast cyclic voltammetry

Synapse

Volumn 32, Issue 3, 1999, Pages 212-224

  Iravani, Mahmoud M ^a   Muscat, Richard ^c   Kruk, Zygmunt L ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF PORTSMOUTH   (United Kingdom)

^c NONE

Author keywords

5 hydroxytryptamine; 5 HT transporter; Axonal release; CPP; Dorsal raphe nucleus; Fast cyclic voltammetry; Methiothepin; MK 801; NMDA; Substantia nigra pars reticulata

Indexed keywords

DIZOCILPINE; FLUVOXAMINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; SEROTONIN; SEROTONIN TRANSPORTER;

ACTION POTENTIAL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CONTROLLED STUDY; CORPUS STRIATUM; CYCLIC POTENTIOMETRY; DORSAL RAPHE NUCLEUS; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; ELECTROSTIMULATION; MALE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SEROTONIN METABOLISM; SEROTONIN RELEASE; SEROTONINERGIC SYSTEM; SIGNAL TRANSDUCTION; SUBSTANTIA NIGRA;

ANIMALS; CARRIER PROTEINS; DIZOCILPINE MALEATE; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRIC STIMULATION; FLUVOXAMINE; HALF-LIFE; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; METHIOTHEPIN; N-METHYLASPARTATE; NERVE TISSUE PROTEINS; PIPERAZINES; RAPHE NUCLEI; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; SEROTONIN; SEROTONIN ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SUBSTANTIA NIGRA;

EID: 0033151480     PISSN: 08874476     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2396(19990601)32:3<212::AID-SYN7>3.0.CO;2-M     Document Type: Article

References (101)

1. Arnt J. 1981. Turning behaviour and catalepsy after injection of excitatory amino acids into rat substantia nigra. Neurosci Lett 23:337-342.
2. Becquet D, Faudon M, Hery F. 1990. In vivo evidence for an inhibitory glutamatergic control of serotonin release in the cat caudate nucleus: involvement of GABA neurons. Brain Res 519:82-88.
3. Becquet D, Hery M, Deprez P, Faudon M, Fache MP, Giraud P, Hery F. 1993. N-methyl-D-aspartic acid/glycine interactions on the control of 5-hydroxytryptamine release in raphe primary cultures. J Neurochem 61:1692-1697.
4. Biggs C, Starr M, Fowler L, Whitton P. 1996. Effects of glutamate antagonists on nigral dopamine release in the reserpine-treated rat. Bio Chem Soc Trans 24:173-177.
5. Bunin MA, Wightman RM. 1998. Quantitative evaluation of 5-hydroxytryptamine (serotonin) neuronal release and uptake: an investigation of extrasynaptic transmission. J Neurosci 18:4854-4860.
6. Bunin MA, Prioleau C, Mailman RB, Wightman RM. 1998. Release and uptake rates of 5-hydroxytryptamine in the dorsal raphé and substantia nigra reticulata of the rat brain. J Neurochem 70:1077-1087.
7. Carter CJ. 1982. Topographic distribution of possible glutamatergic pathways from the frontal cortex to the striatum and substantia nigra in rats. Neuropharmacology 21:379-383.
8. Chergui K, Charléty PJ, Akaoka H, Saunier CF, Brunet JL, Buda M, Svensson TH, Chouvet G. 1993. Tonic activation of NMDA receptors causes spontaneous burst discharge of rat midbrain dopamine neurons in vivo. Eur J Neurosci 5:137-144.
9. Choi DW, Rothman SM. 1990. The role of glutamate neurotoxicity in hypoxic-ischemic neuronal death. Annu Rev Neurosci 13:171-182.
10. Chopin P, Moret C, Briley M. 1994. Neuropharmacology of 5-hydroxytryptamine 1B/D receptor ligands. Pharmacol Ther 62:385-405.
11. Christoffersen CL, Meltzer LT. 1995. Evidence for N-methyl-D-aspartate and AMPA subtypes of the glutamate receptor on substantia nigra dopamine neurons: possible preferential role for N-methyl-D-aspartate receptors. Neuroscience 67:373-381.
12. Clarke PBS, Reuben M. 1995. Inhibition by dizocilpine (MK-801) of striatal dopamine release induced by MPTP and MPP+: possible action at the dopamine transporter. Br J Pharmacol 114:315-322.
13. Clineschmidt BV, Martin GE, Bunting PR, Papp NL. 1982. Central sympathomimetic activity of (+)-5-methyl-10,11-dihydro-5H-dibezo(a,d) cyclohepten-5,10-imine (MK-801), a substance with potent anticonvulsant, central sympathomimetic and apparent anxiolytic properties. Drug Dev Res 2:135-145.
14. Corvaja N, Doucet G, Bolam JP. 1993. Ultrastructure and synaptic targets of the raphe-nigral projection in the rat. Neuroscience 55:417-427.
15. Davidson C, Stamford JA. 1995a. The effect of paroxetine on 5-HT efflux in the rat dorsal raphe nucleus is potentiated by both 5-HT1a and 5-HT1b/d receptor antagonists. Neurosci Lett 188:41-44.
16. Davidson C, Stamford JA. 1995b. Evidence that 5-hydroxytryptamine release in rat dorsal raphe nucleus is controlled by 5-HT1a, 5-HT1b and 5-HT1d autoreceptors. Br J Pharmacol 114:1107-1109.
17. Davies J, Evans RH, Herrling PL, Jones AW, Olverman HJ, Pook P, Watkins JC. 1986. CPP, a new potent and selective NMDA antagonist. Depression of central neuron responses, affinity of [3H]D-AP5 binding sites on brain membranes and anticonvulsant activity. Brain Res 382:169-173.
18. Dawbarn D, Pycock CJ. 1981. Motor effects following application of putative excitatory amino acid antagonists to the region of mesencephalic dopamine cell bodies in the rat. Naunyn Schmiedebergs Arch Pharmacol 318:100-104.
19. Dray A, Gonye TJ, Oakley NR, Tanner T. 1976. Evidence for the existence of a raphe projection to the substantia nigra in the rat. Brain Res 113:45-57.
20. Farfel GM, Vosmer GL, Seiden LS. 1992. The N-methyl-D-aspartate antagonist MK-801 protects against serotonin depletions induced by methamphetamine, 3,4-methylenedioxymethamphetamine and p-chloroamphetamine. Brain Res 595:121-127.
21. Fibiger HC, Miller JJ. 1977. An anatomical and electrophysiological investigation of the serotoninergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 2:975-987.
22. Fink K, Schmitz V, Boing C, Gothert M. 1995. Stimulation of serotonin release in the rat brain cortex by activation of ionotropic glutamate receptors and its modulation via alpha 2-heteroreceptors. Naunyn Schmiedebergs Arch Pharmacol 352:394-401.
23. Freed WJ. 1994. Glutamatergic mechanisms mediating stimulant and antipsychotic drug effects. Neurosci Biobehav Rev 18:111-120.
24. Freeman AS, Bunney BS. 1984. The effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity. Eur J Pharmacol 104:287-293.
25. Gauchy C, Desban M, Glowinski J, Kemel ML. 1994. NMDA regulation of dopamine release from proximal and distal dendrites in the cat substantia nigra. Brain Res 635:249-256.
26. Grace AA, Bunney BS. 1984a. The control of firing pattern in nigral dopamine neurons: burst firing. J Neurosci 4:2877-2890.
27. Grace AA, Bunney BS. 1984b. The control of firing pattern in nigral dopamine neurons: single spike firing. J Neurosci 4:2866-2876.
28. Hery F, Soubrie P, Bourgoin S, Montastruc JL, Artaud F, Glowinski J. 1980. Dopamine released from dendrites in the substantia nigra controls the nigral and striatal release of serotonin. Brain Res 193:143-151.
29. Hiramatsu M, Cho AK, Nabeshima T. 1989. Comparison of the behavioral and biochemical effects of NMDA receptor antagonists, MK-801 and phencyclidine. Eur J Pharmacol 166:359-366.
30. Hjorth S. 1993. Serotonin 5-HT1A autoreceptor blockade potentiates the ability of the 5-HT reuptake inhibitor citalopram to increase nerve terminal output of 5-HT in vivo: a microdialysis study. J Neurochem 60:776-779.
31. Invernizzi R, Belli S, Samanin R. 1992. Citalopram's ability to increase the extracellular concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex. Brain Res 584:322-324.
32. Iravani MM, Kruk ZL. 1992. Effect of NMDA receptor blockade on dopamine overflow in rat caudate putamen. Br J Pharmacol 107: 341P.
33. Iravani MM, Kruk ZL. 1996. Real-time effects of N-methyl-D-aspartic acid on dopamine release in slices of rat caudate putamen: a study using fast cyclic voltammetry. J Neurochem 66:1076-1085.
34. Iravani MM, Kruk ZL. 1997. Real-time measurement of stimulated 5-hydroxytryptamine release in rat substantia nigra pars reticulata brain slices. Synapse 25:93-102.
35. Iravani MM, Muscat R, Kruk ZL. 1996. Comparison of somatodendritic and axon terminal dopamine release in the ventral tegmental area and the nucleus accumbens. Neuroscience 70:1025-1037.
36. Javitt DC, Zukin SR. 1991. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308.
37. Johnson KM, Jones SM. 1990. Neuropharmacology of phencyclidine: basic mechanisms and therapeutic potential. Annu Rev Pharmacol Toxicol 30:707-750.
38. Johnson SW, North RA. 1992. Two types of neurone in the rat ventral tegmental area and their synaptic inputs. J Physiol (Lond) 450:455-468.
39. Kalén P, Karlson M, Wiklund L. 1985. Possible excitatory amino acid afferents to nucleus raphé dorsalis of the rat investigated with retrograde wheat germ agglutinin and D-[3H]aspartate tracing. Brain Res 360:285-297.
40. Kemel ML, Desban M, Glowinski J, Gauchy C. 1989. Distinct presynaptic control of dopamine release in striosomal and matrix areas of the cat caudate nucleus. Proc Natl Acad Sci USA 86:9006-9010.
41. Klockgether T, Turski L. 1989. Excitatory amino acids and the basal ganglia: implications for the therapy of Parkinson's disease. Trends Neurosci 12:285-286.
42. Koek W, Woods JH, Winger GD. 1988. MK-801, a proposed noncompetitive antagonist of excitatory amino acid neurotransmission, produces phencyclidine-like behavioral effects in pigeons, rats and rhesus monkeys. J Pharmacol Exp Ther 245:969-974.
43. Kornhuber J, Kim J-S, Kornhuber M, Kornhuber HH. 1984. The cortico-nigral projection: reduced glutamate content in the substantia nigra following frontal cortex ablation in the rat. Brain Res 322:124-126.
44. Liminga U, Johnson AE, Andren PE, Gunne LM. 1993. Modulation of oral movements by intranigral 5-hydroxytryptamine receptor agoniste in the rat. Pharmacol Biochem Behav 46:427-433.
45. Lodge D, Johnson KM. 1990. Noncompetitive excitatory amino acid receptor antagonists. Trends Pharm Sci 11:81-86.
46. Loscher W, Honack D. 1992. The behavioural effects of MK-801 in rats: involvement of dopaminergic, serotoninergic and noradrenergic systems. Eur J Pharmacol 215:199-208.
47. Loscher W, Annies R, Honack D. 1991. The N-methyl-D-aspartate receptor antagonist MK-801 induces increases in dopamine and serotonin metabolism in several brain regions of rats. Neurosci Lett 128:191-194.
48. Loscher W, Annies R, Honack D. 1993. Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats. Eur J Pharmacol 242:263-274.
49. Mele A, Thomas DN, Pert A. 1998. Different neural mechanisms underlie dizocilpine maleate- and dopamine agonist-induced locomtor activity. Neuroscience 82:43-58.
50. Mereu G, Costa E, Armstrong DM, Vicini S. 1991. Glutamate receptor subtypes mediate excitatory synaptic currents of dopamine neurons in midbrain slices. J Neurosci 11:1359-1366.
51. Mori S, Matsuura T, Takino T, Sano Y. 1987. Light and electron microscopic immunohistochemical studies of serotonin nerve fibers in the substantia nigra of the rat, cat and monkey. Anat Embryol Berl 176:13-18.
52. Mount H, Welner S, Quirion R, Boksa P. 1989. Glutamate stimulation of (3H)dopamine release from dissociated cell cultreus of rat ventral mesencephalon. J Neurochem 52:1300-1310.
53. Murase S, Mathe JM, Grenhoff J, Svensson TH. 1993. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization. J Neural Transm Gen Sect 91:13-25.
54. Nabeshima T, Yamaguchi K, Hiramatsu M, Amano M, Furukawa H, Kameyama T. 1984. Serotoninergic involvement in phencyclidine-induced behaviours. Pharmacol Biochem Behav 1:401-408.
55. Nabeshima T, Hiramatsu M, Furukawa H, Kameyama T. 1985. Effects of acute and chronic administrations of phencyclidine on the levels of serotonin and 5-hydroxyindoleacetic acid in discrete brain areas of mouse. Life Sci 36:939-46.
56. Nabeshima T, Yamaguchi K, Yoshida S, Furukawa H, Kameyama T. 1986. Phencyclidine-induced wet-dog shakes observed in rats after withdrawal from reserpine treatment. Pharmacol Biochem Behav 24:1275-1279.
57. Nedergaard S, Bolam JP, Greenfield SA. 1988. Facilitation of a dendritic calcium conductance by 5-hydroxytryptamine in the substantia nigra. Nature 333:174-177.
58. Nicholas AP, Pieribone VP, Arvidsson U, Hokfelt T. 1992. Serotonin-, substance P, and glutamate/aspartate-like immunoreactivities in medullo-spinal pathways of rat and primates. Neuroscience 48:545-559.
59. Nieoullon A, Cheramy A, Glowinski J. 1978. Release of dopamine in both caudate nuclei and substantia nigrae in response to unilateral stimulation of cerebellar nuclei in the cat. Brain Res 148:143-152.
60. O'Connor JJ, Kruk ZL. 1991a. Fast cyclic voltammetry can be used to measure stimulated endogenous 5-hydroxytryptamine release in untreated rat brain slices. J Neurosci Methods 38:25-33.
61. O'Connor JJ, Kruk ZL. 1991b. Frequency dependence of 5-HT autoreceptor function in rat dorsal raphe and suprachiasmatic nuclei studied using fast cyclic voltammetry. Brain Res 568:123-130.
62. O'Connor JJ, Kruk ZL. 1992. Pharmacological characteristics of 5-hydroxytryptamine autoreceptors in rat brain slices incorporating the dorsal raphe or the suprachiasmatic nucleus. Br J Pharmacol 106:524-532.
63. O'Connor JJ, Kruk ZL. 1994. Effects of 21 days treatment with fluoxetine on stimulated endogenous 5-hydroxytryptamine overflow in the rat dorsal raphe and suprachiasmatic nucleus studied using fast cyclic voltammetry in vitro. Brain Res 640:328-335.
64. Ohmori T, Koyama T, Nakamura F, Wang P, Yamashita I. 1992. Effect of phencyclidine on spontaneous and N-methyl-D-aspartate (NMDA)-induced efflux of dopamine from superfused slices of rat striatum. Neuropharmacology 31:461-467.
65. Ohmori T, Koyama T, Muraki A, Yamashita I. 1993. Competitive and noncompetitive N-methyl-D-aspartate antagonists protect dopaminergic and serotoninergic neurotoxicity produced by methamphetamine in various brain regions. J Neural Transm Gen Sect 92:97-106.
66. Olivier V, Guibert B, Leviel V. 1995. Direct in vivo comparison of two mechanisms releasing dopamine in the rat striatum. Brain Res 695:1-9.
67. Ottersen OP, Storm Mathisen J. 1984. Glutamate- and GABA-containing neurons in the mouse and rat brain, as demonstrated with a new immunocytochemical technique. J Comp Neurol 229:374-392.
68. Overton P, Clark D. 1992. Iontophoretically administered drugs acting at the N-methyl-D-aspartate receptor modulate burst firing in A9 dopamine neurons in the rat. Synapse 10:131-140.
69. Palkovits M, Brownstein M, Saavedra JM. 1974. Serotonin content of the brain stem nuclei in the rat. Brain Res 80:237-249.
70. Paxinos G, Watson C. 1986. The rat brain in stereotaxic coordinates. London: Academic Press.
71. Porceddu ML, Piacente B, Morelli M, Di Chiara G. 1979. Opposite turning effects of kainic and ibotenic acid injected in the rat substantia nigra. Neurosci Lett 15:271-276.
72. Prehn JH, Welsch M, Backhauss C, Nuglisch J, Ausmeier F, Karkoutly C, Krieglstein J. 1993. Effects of serotonergic drugs in experimental brain ischemia: evidence for a protective role of serotonin in cerebral ischemia. Brain Res 630:10-20.
73. Pycock CJ, Dawbarn D. 1980. Acute motor effects of N-methyl-D-aspartic acid and kinic acid applied focally to mesencephalic dopamine cell body regions in the rat. Neurosci Lett 18:85-90.
74. Pycock CJ, Dawbarn D. 1981. Acute motor effects of N-methyl-D-aspartic acid (NMDA) and kainic acid applied focally to mesencephalic dopamine cell body region in the rat. Neurosci Lett 18:85-90.
75. Rao TS, Kim HS, Lehmann J, Martin LL, Wood PL. 1990. Interaction of phencyclidine receptor agonist MK-801 with dopaminergic system: regional studies in the rat. J Neurochem 54:1157-1162.
76. Reisine T, Soubrié P, Artaud F, Glowinski J. 1982. Application of L-glutamic acid and substance P to the substantia nigra modulated in vivo 3H-release in the basal ganglia of the cat. Brain Res 236:317-328.
77. Roberts PJ, Anderson SD. 1979. Stimulatory effect of L-glutamate and related amino acids on [3H]dopamine release from rat striatum: an in vitro model of glutamate actions. J Neurochem 32:1539-1545.
78. Romo R, Chéramy A, Godeheu G, Glowinski J. 1986. In vivo presynaptic control of dopamine release in the cat caudate nucleus. III. Further evidence for the implication of corticostriatal glutamatergic neurons. Neuroscience 19:1091-1099.
79. Romoa AS, Alkondon M, Aracava Y, Irons J, Lunt GG, Deshpande SS, Wonnacott S, Aronstam RS, Albaquerque EX. 1990. The anticonvulsant MK-801 interacts with peripheral and central nicotinic acetylcholine receptor ion channel. J Pharmacol Exp Ther 254:71-82.
80. Smith RC, Meltzer HY, Arora RC, Davis JM. 1977. Effects of phencyclidine on [3H]catecholamine and [3H]serotonin uptake in synaptosomal preparations from rat brain. Biochem Pharmacol 26:1435-1439.
81. Snell LD, Yi S-J, Johnson KM. 1988. Comparison of the effects of MK-801 and phencyclidine on catecholamine uptake and NMDA-induced norepinephrine release. Eur J Pharmacol 145:223.
82. Stamford JA, Kruk ZL, Millar J. 1990. Striatal dopamine terminals release serotonin after 5-HTP pretreatment: in vivo voltammetric data. Brain Res 515:173-180.
83. Steinbusch HWM. 1981. Distribution of serotonin-immunoreactivity in the central nervous system of the rat cell bodies and terminals. Neuroscience 6:557-618.
84. Svensson TH, Mathe JM, Andersson JL, Nomikos GG, Hildebrand BE, Marcus M. 1995. Mode of action of atypical neuroleptics in relation to the phencyclidine model of schizophrenia: role of 5-HT2 receptor and alpha 1-adrenoceptor antagonism. J Clin Psychopharmacol 15:11S-18S. [Published erratum appears in J Clin Psychopharmacol 1995 15:154.]
85. Tabatabaei A, Perry TL, Hansen S, Krieger C. 1992. Partial protective effect of MK-801 on MPTP-induced reduction of striatal dopamine in mice. Neurosci Lett 141:192-194.
86. Tao R, Auerbach SB. 1996. Differential effect of NMDA on extracellular serotonin in rat midbrain raphe and forebrain sites. J Neurochem 66:1067-1075.
87. Trent F, Tepper JM. 1991. Dorsal raphe stimulation modifies striatal-evoked antidromic invasion of nigral dopaminergic neurons in vivo. Exp Brain Res 84:620-630.
88. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD. 1989. The behavioral effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptors. Eur J Pharmacol 167:127-135.
89. Trujillo KA, Akil H. 1991. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 251:85-87.
90. Turski L, Bressler K, Rettig KJ, Loschmann PA, Wachtel H. 1991. Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists [see Comments]. Nature 349:414-418.
91. Vandermaelen CP, Aghajanian GK. 1983. Electrophysiological and pharmacological characterization of serotonergic dorsal raphe neurones recorded extracellularly and intracellularly in rat brain slices. Brain Res 289:109-119.
92. Vandermaelen CP, Matheson GK, Wilderman RC, Patterson LA. 1986. Inhibition of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, a non-benzodiazepine anxiolytic drug. Eur J Pharmacol 129:123-130.
93. Verma A, Kulkarni SK. 1992. Modulation of MK-801 response by dopaminergic agents in mice. Psychopharmacology 107:431-436.
94. Westerink BH, Santiago M, De-Vries JB. 1992. The release of dopamine from nerve terminals and dendrites of nigrostriatal neurons induced by excitatory amino acids in the conscious rat. Naunyn Schmiedebergs Arch Pharmacol 345:523-529.
95. Whitton PS, Biggs CS, Pearce BR, Fowler LJ. 1992. MK-801 increases extracellular 5-hydroxytryptamine in rat hippocampus and striatum in vivo. J Neurochem 58:1573-1575.
96. Williams J, Davies JA. 1983. The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of rat substantia nigra. J Pharm Pharmacol 35:734-737.
97. Wolf ME, Khansa MR. 1991. Repeated administration of MK-801 produces sensitization to its own locomotor stimulant effects but blocks sensitization to amphetamine. Brain Res 562:164-168.
98. Wolf ME, White FJ, Hu XT. 1993. Behavioral sensitization to MK-801 (dizocilpine) - neurochemical and electrophysiological correlates in the mesoaccumbens dopamine system. Behav Pharmacol 4:429-442.
99. Wong EH, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL. 1986. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA 83:7104-7108.
100. Yan QS, Reith ME, Jobe PC, Dailey JW. 1997. Dizolcilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmission in the nucleus accumbens as measured by microdialysis in freely moving rats. Brain Res 765:149-158.
101. Zhang H, Kiyatkin EA, Stein EA. 1994. Behavioral and pharmacological modulation of ventral tegmental dendritic dopamine release. Brain Res 656:59-70.